NuVasive Receives a Hold from Robert W. Baird

By Ryan Adsit

Robert W. Baird analyst Jeff Johnson reiterated a Hold rating on NuVasive (NASDAQ: NUVA) today and set a price target of $55. The company’s shares opened today at $48.45, close to its 52-week low of $44.62.

According to, Johnson is a 4-star analyst with an average return of 8.5% and a 62.5% success rate. Johnson covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, Zimmer Biomet Holdings, and Wright Medical Group.

Currently, the analyst consensus on NuVasive is Strong Buy and the average price target is $65, representing a 34.2% upside.

In a report released today, Leerink Partners also maintained a Hold rating on the stock with a $52 price target.

The company has a one-year high of $81.68 and a one-year low of $44.62. Currently, NuVasive has an average volume of 900K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NuVasive, Inc. is medical device company, which engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V.